Oncology

The 2012 New York ASCO Checklist

Getting On Pathway?

Testing for ALK-Positive NSCLC

Keith Beagin

Jennifer Klemm, PhD;Stanton R. Mehr

Signaling the Future of Personalized Medicine

Prostate Cancer

Long-Term Breast Cancer Patient Follow-Up Care

Anna Azvolinsky, PhD

Myeloproliferative Disorders and Myelofibrosis

Money Well Spent?

Marjorie P. Zimmerman, MS, BSPharm, RPh;Stanton R. Mehr

BRCA1/2 Genetic Testing Found Cost-Effective in Current Era

Alice Goodman

Trends in the 2012 Eisai Oncology Digest: Patient Demographics and Cancer Treatment Goals

SABCS Conference Coverage

This article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned and funded by Eisai Inc.

Literature Review

On the Horizon for Multiple Myeloma

Multiple Myeloma: Pre-Transplant Induction, Consolidation, and Maintenance Therapy

Michael Marlan Mohundro, PharmD;Brice Labruzzo Mohundro, PharmD

Oncology Hit Hard by SGR Debacle

Availability of Newer Agents May Lower Healthcare Costs

First Cancer-Specific ACO Launches

Interview With Allen S. Lichter, MD, Chief Executive Officer, American Society of Clinical Oncology

Forging a Pathway to Quality Cancer Care

Kim Farina, PhD

Is Provenge Angst a Symbol or Symptom of the Times?

UPMC Oncologists: Pioneers in the Clinical Pathways Movement

Dawn G. Holcombe, MBA, FAMCPE, ACHE

Chronic Myelogenous Leukemia

Jennifer Klemm, PhD;Stanton R. Mehr

Economic Benefits of BIS-Aided Assessment of Post-BC Lymphedema in the United States

Sara P. Bilir, MS;Mitchell P. DeKoven, MHSA;Juliet Munakata, MS

Docs Need Primer on Long-Term Effects of Chemotherapy

Use of bioimpedance spectroscopy to aid in post“breast cancer assessments for lymphedema can be cost saving for healthcare organizations in the United States.

May 22nd 2012

Many primary care physicians - and even some oncologists - are unaware of common long-term side effects of four widely used breast and colorectal cancer drugs, a national survey by the National Cancer Institute reveals.

Implementation of Cancer Clinical Care Pathways: A Successful Model of Collaboration Between Payers and Providers

Bruce A. Feinberg, DO;James Lang, PharmD, MBA;James Grzegorczyk, MS, RPh;Donna Stark, RPh, MBA;Thomas Rybarczyk, RN, BSN;Thomas Leyden, MBA;Joseph Cooper;Thomas Ruane, MD;Scott Milligan, PhD;Philip Stella, MD;Jeffrey A. Scott, MD

Payer Coverage for Patients Enrolled Onto Clinical Trials: Making the Process Easy and Transparent for Everyone

A statewide collaboration between payers and providers to create a cancer clinical care pathways program is successful.

Carol S. Palackdharry, MD, MS;David L. Evans, MD;Robert S. McDonough, MD;Melissa E. Clarke, MD;James D. Cross, MD;Ira M. Klein, MD, MBA;Lonny Reisman, MD

Oncology Patient-Centered Medical Home

It is not just 1 physician who cares for a patient enrolled onto a clinical trial but rather a complex system of several physician teams, sometimes with very different opinions, who must work together for therapy to be successful and for the patient to have faith in his treating team.

John D. Sprandio, MD, FACP

ASCO '12 Abstract Dump: Cancer Stocks in Focus

The oncology patient“centered medical home is a physician-driven, patient-focused value proposition that can make a difference for patients, oncologists, and the cost of healthcare.